Evidence map›Paper›PMID 19549809›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2009

Fine-mapping and family-based association analyses of prostate cancer risk variants at Xp11.

Lingyi Lu, Jielin Sun, Sarah D Isaacs, Kathleen E Wiley, Shelly Smith, Kristen Pruett, Yi Zhu, Zheng Zhang, Fredrik Wiklund, Henrik Grönberg and 5 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis.International journal of clinical and experimental medicine · 2015
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lingyi LuCenter for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Jielin Sun
Sarah D Isaacs
Kathleen E Wiley
Shelly Smith
Kristen Pruett
Yi Zhu
Zheng Zhang
Fredrik Wiklund
Henrik Grönberg
Patrick C Walsh
Bao-Li Chang
S Lilly Zheng
William B Isaacs
Jianfeng Xu

Funding

TRANSGENIC MODELS FOR PROSTATE CANCER AND AUTOIMMUNITYP50CA058236 · NCI · JOHNS HOPKINS UNIVERSITY · PI DENMEADE, SAMUEL R · 1992 to 2020
$43.9M
Confirmation of SNPs Associated with Aggressive PCa in a GWA StudyR01CA129684 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XU, JIANFENG · 2008 to 2011
$2.4M
Genetic Susceptibility for Prostate Cancer ProgressionR01CA112517 · NCI · JOHNS HOPKINS UNIVERSITY · PI ISAACS, WILLIAM B · 2005 to 2009
$2.0M
Interaction of PTEN and CDKN1B in Pca susceptibilityR01CA106523 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XU, JIANFENG · 2004 to 2008
$1.6M
Mapping Prostate Cancer Susceptibility Genes at 8p22-23R01CA095052 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI XU, JIANFENG · 2003 to 2007
$1.4M
NCI NIH HHS CA106523NCI NIH HHS CA112517NCI NIH HHS CA129684NCI NIH HHS CA58236NCI NIH HHS CA95052NCI NIH HHS P50 CA058236NCI NIH HHS R01 CA095052NCI NIH HHS R01 CA106523NCI NIH HHS R01 CA112517NCI NIH HHS R01 CA129684
6 · The paper itself

Abstract

Two single nucleotide polymorphisms (SNP; rs5945572 and rs5945619) at Xp11 were recently implicated in two genome-wide association studies of prostate cancer. Using a family-based association test for these two SNPs in 168 families with prostate cancer, we showed in this study that the risk alleles of the two reported SNPs were overtransmitted to the affected offspring (P= 0.009 for rs5945372 and P = 0.03 for rs5945619), which suggested that the observed association in case-control studies were not driven by potential population stratification. We also did a fine-mapping study in the approximately 800 kb region at Xp11 between two independent case-control studies, including 1,527 cases and 482 controls from Johns Hopkins Hospital and 1,172 cases and 1,157 controls from the Prostate, Lung, Colon and Ovarian Cancer screening trial. The strongest association was found with SNPs in the haplotype block in which the two initial reported SNPs were located, although many SNPs in the approximately 140 kb region were highly significant in the combined allelic tests (P = 10(-5) to 10(-6)). The second strongest association was observed with SNPs in the approximately 286 kb region at another haplotype block (P = 10(-4) to 10(-5)), approximately 94 kb centromeric to the first region. The significance of SNPs in the second region decreased considerably after adjusting for SNPs at the first region, although P values remained at <0.05. Additional studies are warranted to test independent prostate cancer associations at these two regions.

Indexed as

Case-Control StudiesChromosome MappingChromosomes, Human, XGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHumansMalePedigreePolymorphism, Single NucleotideProstatic NeoplasmsRisk FactorsUnited States

Identifiers

PMID19549809
PMCPMC2795389

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.